Thermo Fisher Scientific Toekomstige groei
Future criteriumcontroles 1/6
Thermo Fisher Scientific zal naar verwachting groeien in winst en omzet met respectievelijk 11.8% en 5.7% per jaar. De winst per aandeel zal naar verwachting groeien met 11.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17.5% zijn.
Belangrijke informatie
11.8%
Groei van de winst
11.6%
Groei van de winst per aandeel
| Life Sciences winstgroei | 18.4% |
| Inkomstengroei | 5.7% |
| Toekomstig rendement op eigen vermogen | 17.5% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 01 Nov 2024 |
Recente toekomstige groei-updates
Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Apr 27
Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results
Feb 02Recent updates
Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
Oct 23Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Oct 04These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
Sep 21Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings
Aug 16Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Jul 25A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 11Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Jun 18Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends
Jun 07Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)
Apr 30Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Apr 27Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
Apr 24Thermo Fisher Scientific: Too Hot To Handle
Apr 15Investors Still Waiting For A Pull Back In Thermo Fisher Scientific Inc. (NYSE:TMO)
Apr 02We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt
Mar 12Thermo Fisher's Bright Future Makes It A Great Buy On Weakness
Feb 06Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results
Feb 02Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics
Jan 16Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With 'Hold'
Jan 06Is Now An Opportune Moment To Examine Thermo Fisher Scientific Inc. (NYSE:TMO)?
Dec 29Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?
Dec 11Thermo Fisher Scientific: I Am Still Waiting For An Attractive Buying Opportunity.
Dec 02Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 48,443 | 8,176 | 9,767 | 11,075 | 22 |
| 12/31/2025 | 45,139 | 7,031 | 8,822 | 9,872 | 27 |
| 12/31/2024 | 42,816 | 6,146 | 6,980 | 8,097 | 27 |
| 9/28/2024 | 42,370 | 6,135 | 7,775 | 9,100 | N/A |
| 6/29/2024 | 42,346 | 6,220 | 7,963 | 9,348 | N/A |
| 3/30/2024 | 42,492 | 6,034 | 7,560 | 8,928 | N/A |
| 12/31/2023 | 42,857 | 5,995 | 6,927 | 8,406 | N/A |
| 9/30/2023 | 43,421 | 5,941 | 6,546 | 8,170 | N/A |
| 7/1/2023 | 43,524 | 5,721 | 5,854 | 7,693 | N/A |
| 4/1/2023 | 43,807 | 6,024 | 5,620 | 7,681 | N/A |
| 12/31/2022 | 44,915 | 6,950 | 6,911 | 9,154 | N/A |
| 10/1/2022 | 44,167 | 7,032 | 5,600 | 8,124 | N/A |
| 7/2/2022 | 42,820 | 7,439 | 6,336 | 8,837 | N/A |
| 4/2/2022 | 41,123 | 7,603 | 7,001 | 9,536 | N/A |
| 12/31/2021 | 39,211 | 7,725 | 6,789 | 9,312 | N/A |
| 10/2/2021 | 39,059 | 8,565 | 7,916 | 10,194 | N/A |
| 7/3/2021 | 38,250 | 8,596 | 8,132 | 10,252 | N/A |
| 4/3/2021 | 35,894 | 7,924 | 8,062 | 9,911 | N/A |
| 12/31/2020 | 32,218 | 6,375 | 6,815 | 8,289 | N/A |
| 9/26/2020 | 28,497 | 4,879 | 5,686 | 6,863 | N/A |
| 6/27/2020 | 26,248 | 3,706 | 4,245 | 5,272 | N/A |
| 3/28/2020 | 25,647 | 3,669 | 3,702 | 4,680 | N/A |
| 12/31/2019 | 25,542 | 3,696 | 4,047 | 4,973 | N/A |
| 9/28/2019 | 25,220 | 3,592 | 3,940 | 4,861 | N/A |
| 6/29/2019 | 24,868 | 3,541 | 4,086 | 4,964 | N/A |
| 3/30/2019 | 24,630 | 3,174 | 4,273 | 5,114 | N/A |
| 12/31/2018 | 24,358 | 2,938 | 3,785 | 4,543 | N/A |
| 9/29/2018 | 23,898 | 2,570 | 3,919 | 4,608 | N/A |
| 6/30/2018 | 23,094 | 2,395 | N/A | 4,317 | N/A |
| 3/31/2018 | 22,006 | 2,256 | N/A | 3,722 | N/A |
| 12/31/2017 | 20,918 | 2,228 | N/A | 4,005 | N/A |
| 9/30/2017 | 19,824 | 2,330 | N/A | 3,344 | N/A |
| 7/1/2017 | 19,199 | 2,270 | N/A | 3,220 | N/A |
| 4/1/2017 | 18,744 | 2,174 | N/A | 3,284 | N/A |
| 12/31/2016 | 18,274 | 2,025 | N/A | 3,258 | N/A |
| 10/1/2016 | 17,973 | 1,999 | N/A | 3,281 | N/A |
| 7/2/2016 | 17,606 | 2,003 | N/A | 3,220 | N/A |
| 4/2/2016 | 17,341 | 1,998 | N/A | 3,072 | N/A |
| 12/31/2015 | 16,965 | 1,980 | N/A | 2,942 | N/A |
| 9/26/2015 | 16,806 | 1,978 | N/A | 2,543 | N/A |
| 6/27/2015 | 16,854 | 1,971 | N/A | 2,475 | N/A |
| 3/28/2015 | 16,905 | 1,738 | N/A | 2,598 | N/A |
| 12/31/2014 | 16,890 | 1,896 | N/A | 2,620 | N/A |
| 9/27/2014 | 15,864 | 1,635 | N/A | 2,394 | N/A |
| 6/28/2014 | 14,884 | 1,482 | N/A | 2,224 | N/A |
| 3/29/2014 | 13,802 | 1,481 | N/A | 1,814 | N/A |
| 12/31/2013 | 13,090 | 1,279 | N/A | 2,011 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei TMO ( 11.8% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van TMO ( 11.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).
Hoge groeiwinsten: De winst van TMO zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van TMO ( 5.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.8% per jaar).
Hoge groei-inkomsten: De omzet van TMO ( 5.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen TMO zal naar verwachting over 3 jaar laag zijn ( 17.5 %).